
    
      Purpose: In an open-label randomized phase II trial, patients with metastatic Human Epidermal
      Growth Factor Receptor 2-negative breast cancer with normal organ function sant WHO
      performance status < 3 are randomized to receive either capecitabine (day 1-14) plus
      vinorelbine oral (day 1 and 8) or capecitabine (day 1-14) plus vinorelbine oral metronomic (3
      days a week).
    
  